When a laboratory reports a drug, protein or chemical marker in a biological sample, the number can look precise. But what if the specimen was wrong, the compound was misidentified or the calibration did not cover that concentration? The gold standard of bioanalysis is a measurement of a specifically identified analyte in the intended biological matrix, supported by suitable validation, trustworthy sample records and a conclusion limited to what the assay establishes.
This 20-chapter guide connects Analytical Chemistry, Spectroscopy, Biochemistry, Biostatistics, Clinical Research and Biomonitoring. It follows the measured signal into scientific interpretation and explains three fictional examples of quantitative error.
Quick information: what credible bioanalysis must document
Specify the analyte, sample identity and matrix, scientific purpose, selectivity, calibrated range, precision and accuracy, sample handling, stability, quality controls, dilution and retention records, method version, applicable guidance and uncertainty. A validated number is not automatically a diagnosis or treatment decision.
Five routes through bioanalysis
Full 20-chapter index
1. Define bioanalysis by its intended result · 2. Separate molecular identity from the reported quantity · 3. Choose the biological matrix before validation · 4. Read sampling times in relation to biology · 5. Understand selectivity and specificity without overclaiming · 6. Build calibration using evidence rather than an attractive line · 7. Treat lower and upper quantification limits honestly · 8. Distinguish bias, accuracy and precision · 9. Keep sample preparation and recovery visible · 10. Recognise when dilution changes the meaning of a number · 11. Understand stability as time-and-condition dependent · 12. Separate method validation from routine sample assurance · 13. Worked fictional case: a reference and a biased value · 14. Worked fictional case: repeatability is not trueness · 15. Worked fictional case: dilution factor and quantification · 16. Separate biomarkers from drug-quantification rules · 17. Keep study provenance, audit trails and data governance intact · 18. Apply bioanalysis honestly to drug and clinical decisions · 19. Build a balanced laboratory quality scorecard · 20. Teach bioanalysis as chemistry joined to trustworthy decisions
1. Define bioanalysis by its intended result
Bioanalysis is the measurement and interpretation of defined substances in biological material. In regulated drug development, it often concerns concentrations of medicines and their metabolites in matrices such as plasma, serum or urine; other applications examine biomarkers, proteins, cell products or environmentally relevant chemicals. A method suitable for one analyte and purpose may be unsuitable for another.
The gold standard begins with the intended analyte, specimen, scientific decision, accuracy requirements and evidence that the method is fit for purpose. Analytical Chemistry, Biochemistry and Clinical Research explain its disciplinary setting. The EMA guidance on ICH M10 applies to relevant drug quantification, not every possible biology assay.
Evidence check: What precise decision will the reported concentration support, and has the measurement method been validated for that decision?
2. Separate molecular identity from the reported quantity
An assay’s signal can be affected by chemically similar compounds and interfering substances. A chromatographic peak, fluorescence intensity or immunoassay response cannot be assumed to identify one specific molecule in every sample. Identity and specificity must be supported using methods suitable for the analyte and matrix.
Quantification requires an established connection between measured response and concentration. The Spectroscopy, Analytical Chemistry and Biochemistry roots help show why identification and amount are separate claims. Higher signal is not automatically a larger amount of the intended molecule.
Evidence check: Can a second analyst identify which compound the signal represents, not merely observe that a detector responded?
3. Choose the biological matrix before validation
Blood, serum, plasma, urine, tissue and other matrices differ in chemical and physical composition. Matrix effects may suppress or enhance a detector signal, alter extraction efficiency or create interference. A method validated for plasma should not automatically be advertised as suitable for a different specimen without appropriate evidence.
ICH M10 stresses validation in the relevant study matrix, with particular treatment of justified surrogate matrices. Biomonitoring, Clinical Research and Chemistry connect sampling to analytical validity. Anticoagulants, storage and collection materials may also matter.
Evidence check: Does the validation matrix genuinely match the samples that generated the reported results?
4. Read sampling times in relation to biology
A concentration may change rapidly after exposure or drug administration, while some analytes persist much longer. Sampling at a different time can produce a different value without the method being wrong. A single endpoint rarely reconstructs the full time course of a substance moving through a biological system.
A scientifically defensible report documents collection time relative to the relevant event, specimen identity, time interval and handling conditions. Biochemistry, Clinical Research and Biostatistics help distinguish real biological variation from methodological change.
Evidence check: Were all compared samples collected at biologically comparable times and with the necessary contextual information?
5. Understand selectivity and specificity without overclaiming
Selectivity concerns the method’s ability to quantify the intended substance in the presence of other sample components under defined conditions. Specificity, interference and assay design have distinct meanings depending on technology. Biological samples are complex; a clean solvent standard does not demonstrate performance in every actual patient specimen.
The FDA’s final M10 bioanalytical method guidance addresses chromatographic and ligand-binding assays for its regulated scope. Analytical Chemistry and Spectroscopy extend the scientific methods.
Evidence check: Which likely interfering materials were examined, and how did the report document the method’s ability to distinguish the analyte?
6. Build calibration using evidence rather than an attractive line
A calibration model relates instrument response to known amounts of an analyte over a defined range. Good appearance on a graph is not enough: calibration levels, fitted model, residuals, controls and accuracy at relevant concentrations matter. Extrapolating far beyond a validated range can create precise-looking but unreliable values.
The right model depends on method and purpose. Chemistry, Biostatistics and Analytical Chemistry support sensible quantitative interpretation. Concentration values should be reported in the correct units for the specified matrix.
Evidence check: Can the claimed concentration be reconstructed from the calibration and its valid measurement interval?
7. Treat lower and upper quantification limits honestly
A lower limit of quantification defines the lowest concentration shown to meet relevant quantitative performance criteria under the method. A detection limit answers a related but different question, and an upper limit of quantification bounds high measurements. Samples outside the validated range require an appropriate reporting and analysis decision.
A result below quantification is not automatically zero, and a high result beyond range should not be converted from an unchecked signal into a final concentration. Analytical Chemistry, Chemistry and Biomonitoring connect these principles.
Evidence check: Did the analyst preserve the distinction between absent signal, detectable signal and a reliably quantified amount?
8. Distinguish bias, accuracy and precision
Accuracy describes closeness to an appropriate reference, while precision concerns agreement among repeated measurements. A set of tightly grouped results can be consistently wrong. Conversely, a method whose average is near the reference may have unacceptable scatter for an important decision.
Validation uses appropriately designed quality-control material and replicate observations to characterise method performance over the intended range. The FDA ICH Q2(R2) validation guidance provides a broader analytic framework beyond the drug-quantification scope of M10.
Evidence check: Do the quality checks independently establish both the centre and the variability of the reported values?
9. Keep sample preparation and recovery visible
Biological specimens can require processing before analysis, and analyte loss or variable extraction may alter the observed signal. A high recovery in one clean control may not generalise to patient samples with different composition. Carryover from earlier samples, instrument contamination or handling losses also deserve appropriate examination.
A robust bioanalysis report records the validated preparation method, sample condition and how relevant recovery or carryover issues were assessed, without treating this article as a laboratory protocol. Analytical Chemistry and Biochemistry supply scientific context.
Evidence check: Can a reader tell whether low concentration reflects the sample or a loss introduced during processing?
10. Recognise when dilution changes the meaning of a number
Analysts sometimes dilute a specimen to bring its response into an instrument’s quantified range. The final concentration then depends on the correct factor and on whether dilution integrity has been appropriately established. Errors can arise from confusing a one-in-four final dilution with adding four volumes of liquid to one volume of specimen.
A quality report preserves the dilution convention, calculation, applicable validated range and any limitations. Chemistry, Biostatistics and Analytical Chemistry explain the quantitative reasoning. The example in chapter 15 tests this specific error.
Evidence check: Was the result adjusted with the actual final-volume ratio, and was the diluted measurement itself trustworthy?
11. Understand stability as time-and-condition dependent
The concentration or chemical form of an analyte may change during collection, handling, storage and analysis. Stability can depend on matrix, duration, temperature and processing. A method that accurately analyses a fresh prepared sample may give the wrong result when old specimens have changed before measurement.
The appropriate investigation is defined by the study’s real sample conditions and intended use; it should not copy one general stability statement across unrelated substances. Biochemistry, Pharmaceutical Companies and Analytical Chemistry provide related standards.
Evidence check: Do the validation and documentation cover the actual handling history that produced the reported values?
12. Separate method validation from routine sample assurance
A fully documented method-validation exercise is not proof that every future sample run will succeed. Subsequent analyses must maintain controls, check system performance, record deviations and manage changes. Incurred sample reanalysis can be relevant under ICH M10 when specified; it examines reproducibility using actual study samples, not just prepared calibration controls.
The ICH M10 guidance and associated questions and answers connect method validation to real study samples. Clinical Research and Bioethics explain why unreliable samples can have ethical consequences.
Evidence check: Are routine results supported by the current method and run acceptance evidence, not simply a certificate from an earlier study?
13. Worked fictional case: a reference and a biased value
All numbers in this case are invented. A quality-control material has assigned target concentration 10.0 ng/mL. One reported analysis returns 12.0 ng/mL. The relative difference from the assigned value is (12 − 10) ÷ 10 × 100 = +20%. That is an observed relative bias for this simplified single result, not a statement that the method always has exactly 20% bias.
A full assessment requires an appropriate number of replicates, levels, matrix controls and validation rules matching the intended assay. Analytical Chemistry and Biostatistics help interpret the uncertainty.
Evidence check: Was this one measurement overgeneralised into a complete validation result or individual clinical conclusion?
14. Worked fictional case: repeatability is not trueness
Invented repeat readings. Three measurements of a control return 9, 10 and 11 ng/mL. The mean is 10 ng/mL; the sample standard deviation is 1 ng/mL and the illustrative coefficient of variation is 10%. Three points are too few for a serious method-validation claim.
The summary describes repeatability under those specific conditions only. It cannot establish accuracy without a trustworthy reference value, nor reproducibility across laboratories, analysts or dates. Biostatistics and Research Ethics support the broader research-quality discussion.
Evidence check: Does the study distinguish measured scatter from calibration error, matrix effects and untested conditions?
15. Worked fictional case: dilution factor and quantification
Invented teaching calculation. A properly supported one-in-four final dilution of a biological specimen is analysed. The validated assay estimates a concentration of 8 ng/mL in the diluted mixture. If dilution integrity and the defined preparation are appropriate, the original specimen concentration is 8 × 4 = 32 ng/mL.
This arithmetic does not prove the original sample was stable, the assay was selective or the dilution protocol is valid. A signal outside the calibrated range is not magically made valid by multiplying by four. Chemistry, Analytical Chemistry and Clinical Research explain the larger evidence chain.
Evidence check: Were the diluted response and correction both within an appropriately validated analytical method?
16. Separate biomarkers from drug-quantification rules
Biomarkers may be endogenous, variable among individuals and measured to answer different research or clinical questions. Not every biomarker assay can be interpreted by transplanting a drug assay’s assumptions or criteria unchanged. The scientific context, available reference material and decision consequences require appropriate justification.
The FDA’s April 2026 final guidance on biomarker bioanalytical validation addresses this use case. Biomonitoring, Biochemistry and Clinical Research connect the measurements to their intended meanings.
Evidence check: Does the study identify whether it quantifies an administered drug, an endogenous biomarker or a different biological molecule?
17. Keep study provenance, audit trails and data governance intact
Scientific results depend on trustworthy sample identities, collection records, assay versions, instrument logs and analysis changes. Transcription, labelling or data-processing errors can make a precise numerical result refer to the wrong specimen. Privacy adds responsibilities whenever identifiable human material or health information is involved.
Data integrity requires controls that allow authorised review without exposing unnecessary personal information. Bioethics, Research Ethics and Bioinformatics explain the governance and analytical dimensions.
Evidence check: Can an independent authorised reviewer trace each reported concentration to the correct sample and approved analytical version?
18. Apply bioanalysis honestly to drug and clinical decisions
Concentration measurements contribute to pharmacokinetic, toxicokinetic and other regulatory analyses, but a measured drug level is not automatically evidence of efficacy or safety. Clinical interpretation needs study design, dosing context, outcomes, patient variability and appropriate professional review. Research and regulatory evidence operate on different levels.
The Clinical Research, Biostatistics and Pharmaceutical Companies roots connect reliable assay data with wider decision-making. In real practice, current jurisdiction-specific standards and qualified oversight matter.
Evidence check: Is the result presented as an analytical finding, or has it been silently promoted into a clinical recommendation?
19. Build a balanced laboratory quality scorecard
A useful scorecard covers selectivity, calibration, range, bias, precision, relevant stability, sample identity, run quality controls, deviations, data completeness and the reproducibility needed for the intended decision. One excellent precision figure cannot offset serious identification or data-integrity problems.
Hard quality failures deserve explicit gates rather than a weighted score that hides them. Analytical Chemistry, Bioethics and Pharmaceutical Companies reinforce accountable laboratory practice. Claims should be revised when methods or relevant specimens change.
Evidence check: Would the quality report still be transparent when the most recent run failed an acceptance condition?
20. Teach bioanalysis as chemistry joined to trustworthy decisions
Students can learn from fictional calibration curves, duplicate measurements and dilution factors without handling real clinical specimens. They should calculate correctly, then identify which missing evidence prevents a clinical or regulatory conclusion. This builds statistical literacy and scientific humility rather than training people to trust a printed number blindly.
The learning route connects Chemistry, Biochemistry, Biostatistics, Biomonitoring and The Gold Standard of Education. The broader Gold Standard series applies the same evidence rules across disciplines.
Evidence check: The final standard is the right molecule measured accurately in the right biological specimen, with a validated method, reproducible calculation, secure provenance and limitations that remain visible.
The existing eduKateSG bioanalysis knowledge web
Chemistry, biology and analytical technologies
Analytical Chemistry · Spectroscopy · Biochemistry · Enzymology · Biology · Cell Biology · Chemistry · Imaging Science
Biological measurement and quantitative interpretation
Biomonitoring · Bioaccumulation · Microbiology · Biostatistics · Bioinformatics
Products, research and governance
Clinical Research · Pharmaceutical Companies · Biotechnology · Biosynthesis · Bioethics · Research Ethics
Return to the series hubs
The Gold Standard of Education · The Gold Standard · Sectors and Services Directory
The wider How X Works hub connects analytical evidence with other systems. The published related roots above serve distinct disciplines; this page joins them around the validity of a biological assay.
Frequently asked questions
What is bioanalysis?
Measuring defined chemical or biological analytes in biological specimens using methods suitable for their intended scientific or regulatory purpose.
Is a strong instrument signal enough to prove a concentration?
No. Identity, selectivity, appropriate calibration and sample-matrix performance must support the quantitative conclusion.
What is the difference between accuracy and precision?
Accuracy concerns closeness to an appropriate reference, while precision concerns scatter between repeat measurements.
What does the lower limit of quantification mean?
The lower end of a validated quantitative range under the method’s relevant performance criteria, distinct from mere detectability.
Why are biological matrix effects important?
Blood, serum, urine and tissues can interfere with an assay differently, so validation must match relevant samples.
What is ICH M10?
A harmonised guideline on bioanalytical method validation and study sample analysis for relevant drug and metabolite assays.
What is new in FDA biomarker validation guidance?
FDA published final guidance on bioanalytical method validation for biomarker concentrations in April 2026, distinct from ICH M10’s drug-quantification scope.
What is the gold standard of bioanalysis?
The correct analyte in the correct specimen, measured by a suitable method with documented quality, traceability and uncertainty.
Current primary analytical guidance and limitations
EMA — ICH M10 Bioanalytical Method Validation and Study Sample Analysis; FDA — Final M10 Bioanalytical Method Guidance, November 2022; FDA — Biomarker Bioanalytical Method Validation, April 2026; FDA — Q2(R2) Analytical Validation, March 2024. Use the appropriate guideline edition and jurisdiction for actual regulatory work.
All worked numerical examples are fictional and do not qualify any real assay or constitute a clinical finding. Real sampling and studies require qualified laboratory personnel, ethical governance and current applicable requirements.